NYSE:CO

Stock Analysis Report

Executive Summary

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Global Cord Blood's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.2%

CO

-0.08%

US Healthcare

1.3%

US Market


1 Year Return

-29.4%

CO

-10.6%

US Healthcare

5.9%

US Market

Return vs Industry: CO underperformed the US Healthcare industry which returned -10.6% over the past year.

Return vs Market: CO underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

COIndustryMarket
7 Day7.2%-0.08%1.3%
30 Day11.6%-4.1%-1.9%
90 Day-16.7%-9.4%-1.8%
1 Year-29.4%-29.4%-9.2%-10.6%8.3%5.9%
3 Year8.3%7.2%28.9%23.7%45.6%36.2%
5 Year0.2%-0.8%58.9%49.4%66.1%47.9%

Price Volatility Vs. Market

How volatile is Global Cord Blood's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Global Cord Blood undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: CO ($4.89) is trading below our estimate of fair value ($17.88)

Significantly Undervalued: CO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CO is good value based on its PE Ratio (12.9x) compared to the Healthcare industry average (19.9x).

PE vs Market: CO is good value based on its PE Ratio (12.9x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CO is good value based on its PB Ratio (1.2x) compared to the US Healthcare industry average (2.4x).


Next Steps

Future Growth

How is Global Cord Blood forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CO's forecast earnings growth (15.2% per year) is above the savings rate (2.7%).

Earnings vs Market: CO's earnings (15.2% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: CO's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if CO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Global Cord Blood performed over the past 5 years?

27.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CO's earnings have grown significantly by 27.7% per year over the past 5 years.

Accelerating Growth: CO's earnings growth over the past year (35%) exceeds its 5-year average (27.7% per year).

Earnings vs Industry: CO earnings growth over the past year (35%) exceeded the Healthcare industry 5.3%.


Return on Equity

High ROE: CO's Return on Equity (9.3%) is considered low.


Return on Assets

ROA vs Industry: CO's Return on Assets is below or equal to the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: CO has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Global Cord Blood's financial position?


Financial Position Analysis

Short Term Liabilities: CO's short term assets (CN¥5.3B) exceeds its short term liabilities (CN¥594.2M)

Long Term Liabilities: CO's short term assets (5.3B) exceeds its long term liabilities (2.6B)


Debt to Equity History and Analysis

Debt Level: CO is debt free.

Reducing Debt: CO has no debt compared to 5 years ago when its debt to equity ratio was 57.5%.

Debt Coverage: CO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CO's debt is covered by short term assets.


Next Steps

Dividend

What is Global Cord Blood's current dividend yield, its reliability and sustainability?

1.55%

Current Dividend Yield


Dividend Yield vs Market

company1.5%marketbottom25%1.5%markettop25%3.8%industryaverage1.7%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: CO's dividend (1.55%) is higher than the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: CO's dividend (1.55%) is low compared to the top 25% of dividend payers in the US market (3.77%).

Stable Dividend: Too early to tell whether CO's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if CO's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (18.7%), CO's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Global Cord Blood's salary, the management and board of directors tenure and is there insider trading?

10.3yrs

Average board tenure


CEO

Tina Zheng (47yo)

0yrs

Tenure

CN¥465,362

Compensation

Ms. Ting Zheng, also known as Tina, serves as the Chief Executive Officer and Chief Executive Officer of Beijing Division of China Cord Blood Corporation and had been its Interim Chief Executive Officer of ...


CEO Compensation Analysis

Compensation vs. Market: Tina's total compensation ($USD465.36K) is about average for companies of similar size in the US market ($USD1.83M).

Compensation vs Earnings: Tina's compensation has been consistent with company performance over the past year.


Board Age and Tenure

10.3yrs

Average Tenure

49yo

Average Age

Experienced Board: CO's board of directors are seasoned and experienced ( 10.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Albert Chen (43yo)

    CFO & Director

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Tina Zheng (47yo)

    Chairperson

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Rui Arashiyama (60yo)

    Chief Executive Officer of Guangdong & Zhejiang Divisions

    • Tenure: 0yrs
    • Compensation: CN¥529.88k
  • Xin Xu (65yo)

    Chief Technology Officer

    • Tenure: 0yrs
    • Compensation: CN¥159.34k
  • Cathy Bai

    Vice President of Corporate Finance

    • Tenure: 0yrs

Board Members

  • Mark D. Chen (51yo)

    Independent Non-Executive Director

    • Tenure: 0yrs
  • Ken Lu (57yo)

    Independent Non-Executive Director

    • Tenure: 10.3yrs
  • Jennifer Weng (51yo)

    Independent Non-Executive Director

    • Tenure: 10.3yrs
  • Albert Chen (43yo)

    CFO & Director

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Tina Zheng (47yo)

    Chairperson

    • Tenure: 0yrs
    • Compensation: CN¥465.36k
  • Ping Xu (40yo)

    Non-Executive Director

    • Tenure: 1.8yrs

Company Information

Global Cord Blood Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Cord Blood Corporation
  • Ticker: CO
  • Exchange: NYSE
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$594.385m
  • Shares outstanding: 121.55m
  • Website: https://www.globalcordbloodcorp.com

Number of Employees


Location

  • Global Cord Blood Corporation
  • Bank of China Tower
  • 48th Floor
  • Central
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CONYSE (New York Stock Exchange)YesOrdinary SharesUSUSDJul 2009
6CBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2009

Biography

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, process ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:52
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.